Austria said there is currently "no evidence of a causal relationship" after one woman died and another developed a pulmonary embolism after receiving doses from the same batch of the COVID-19 vaccine from Oxford-AstraZeneca, BBC News reported on Monday.
The country's Federal Office for Safety in Health Care stated on 7 March 2021 that an investigation was "running at full speed in order to be able to completely exclude a possible connection," adding that the remaining doses from the batch will not be used as a precaution.
However, the Federal Office noted that blood clotting issues "are not among the known or typical side effects of the vaccine in question" and that no similar cases had been linked to the Oxford-AstraZeneca vaccine.
The EU had approved the Oxford-AstrazEneca COVID-19 vaccine in late January 2021.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients